Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 455

1.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

Idris I, Donnelly R.

Diabetes Obes Metab. 2009 Feb;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. Review.

PMID:
19125776
2.

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Jabbour SA, Goldstein BJ.

Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x. Review.

PMID:
18705823
3.

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

DeFronzo RA, Davidson JA, Del Prato S.

Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x. Review.

PMID:
21955459
4.

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.

5.

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.

Chen LH, Leung PS.

Diabetes Obes Metab. 2013 May;15(5):392-402. doi: 10.1111/dom.12064. Epub 2013 Feb 6. Review.

PMID:
23331516
6.

Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus.

Vaidya HB, Goyal RK.

Mini Rev Med Chem. 2010 Sep;10(10):905-13. Review.

PMID:
21034414
7.
8.

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. doi: 10.1517/13543780902766794 . Review.

PMID:
19243283
9.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.

Washburn WN.

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Review.

PMID:
19852718
10.

SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.

Deshmukh AB, Patel MC, Mishra B.

Ren Fail. 2013;35(4):566-72. doi: 10.3109/0886022X.2013.766560. Epub 2013 Feb 25. Review.

PMID:
23438184
11.

Sodium-glucose cotransporter inhibitors for diabetes.

Isaji M.

Curr Opin Investig Drugs. 2007 Apr;8(4):285-92. Review.

PMID:
17458177
12.

SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.

Misra M.

J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9. Review.

PMID:
23356840
13.

A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.

Basile J.

Postgrad Med. 2011 Jul;123(4):38-45. doi: 10.3810/pgm.2011.07.2302. Review.

PMID:
21680987
14.

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors.

Patel AK, Fonseca V.

Curr Diab Rep. 2010 Apr;10(2):101-7. doi: 10.1007/s11892-010-0095-5. Review.

PMID:
20425568
15.

Dapagliflozin for the treatment of type 2 diabetes.

Brooks AM, Thacker SM.

Ann Pharmacother. 2009 Jul;43(7):1286-93. doi: 10.1345/aph.1M212. Epub 2009 Jul 7. Review.

PMID:
19584379
16.

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

Pérez López G, González Albarrán O, Cano Megías M.

Nefrologia. 2010;30(6):618-25. doi: 10.3265/Nefrologia.pre2010.Sep.10494. Review. Spanish.

17.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
18.
19.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
20.

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

Washburn WN.

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019. Review. No abstract available.

PMID:
19243175

Supplemental Content

Support Center